Filing Flows › Tarsus Pharmaceuticals (TARS) › Recalls, complaints & regulation
Tarsus Pharmaceuticals (TARS): clinical trials
Tarsus Pharmaceuticals (TARS) beyond its filings: 3 active clinical trials.
Tarsus Pharmaceuticals' latest quarter
Tarsus Pharmaceuticals, Q3 2026: revenue $195M (+64% year over year), operating margin -340.3%, net loss $668M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Tarsus Pharmaceuticals have?
3 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.